Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors

Next Previous
Search
Trial Profile

A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 2820151 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 07 Oct 2019 Status changed from active, no longer recruiting to discontinued.
  • 30 Mar 2018 Status changed from recruiting to active, no longer recruiting.
  • 24 Apr 2017 Planned primary completion date changed from 1 Mar 2018 to 20 May 2019.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top